コーパス検索結果 (1語後でソート)
  通し番号をクリックするとPubMedの該当ページを表示します
  
   1 tissue inhibitor of metalloproteinases-1 and alpha 2-macroglobulin.                                  
     2 transferrin, alpha-lactalbumin, insulin, and alpha-2-macroglobulin.                                  
     3 immunoprecipitated C4 complement protein and alpha-2-macroglobulin.                                  
     4 (IL-6)-induced acute-phase response protein, alpha(2)-macroglobulin.                                 
     5 wn to be greatly enhanced in the presence of alpha(2)-macroglobulin.                                 
     6 mplete" serum that contains C1-inhibitor and alpha(2)-macroglobulin.                                 
     7 on with the receptor binding domain of human alpha(2)-macroglobulin.                                 
     8 se inhibitor, alpha(1)-antichymotrypsin, and alpha(2)-macroglobulin.                                 
     9 tein in the presence or absence of activated alpha(2)-macroglobulin.                                 
    10 bitors such as tissue inhibitors of MMPs and alpha(2)-macroglobulins.                                
  
    12 st examined whether the acute-phase protein, alpha-2 macroglobulin (A2M), a major component of the in
    13 reaction, nephelometry, and Western blot for alpha-2-macroglobulin (A2M) and activated partial thromb
    14 nse mutation in the evolutionarily conserved alpha-2-macroglobulin (A2M) domain of CPAMD8, c.4351T>C 
  
  
  
    18 se-9, tissue-type plasminogen activator, and alpha(2)-macroglobulin activated Rac1 in LRP1-expressing
    19 a with a mixture of pure C1-inhibitor and/or alpha(2)-macroglobulin added together with MBL-MASP, all
    20 alpha1-proteinase inhibitor (alpha 1-PI) and alpha 2-macroglobulin (alpha 2-M) are reduced, especiall
    21 y of activated factor X (factor Xa) binds to alpha 2-macroglobulin (alpha 2M) and is rapidly cleared 
  
  
  
  
  
  
  
  
  
    31 tron microscopy reconstructions of the human alpha(2)-macroglobulin (alpha(2)M) dimer and chymotrypsi
  
  
  
  
    36 receptor-associated protein and by activated alpha(2)-macroglobulin (alpha(2)M), suggesting the parti
  
  
  
  
  
    42 in receptors by receptor-recognized forms of alpha(2)-macroglobulin (alpha(2)M*) activates various si
    43 tivated form of the pan-proteinase inhibitor alpha(2)-macroglobulin (alpha(2)M*) and amyloid precurso
  
    45 complexed to the receptor-recognized form of alpha(2)-macroglobulin (alpha(2)M*) demonstrate enhanced
    46 ages exposed to receptor-recognized forms of alpha(2)-macroglobulin (alpha(2)M*) demonstrate increase
    47     We report that the LRP ligand, activated alpha(2)-macroglobulin (alpha(2)M*), induces robust calc
    48 rface GRP78 by its natural ligand, activated alpha(2)-macroglobulin (alpha(2)M*), results in a 2-3-fo
  
    50 4 and the receptors for transferrin (Tf) and alpha(2)-macroglobulin (alpha-2-M; LRP-1) were compared 
  
  
    53 G antibody [EndoCAb]), acute-phase proteins (alpha-2 macroglobulin [alpha-2M], C-reactive protein [CR
    54 system, we examined the effects of activated alpha(2)-macroglobulin (alpha2M*), a ligand of LRP, on i
  
    56 ayer-by-layer (LbL) microcapsules to deliver alpha-2-macroglobulin (alpha2MG), a protein with modulat
    57 nt role in the clearance of plasma-activated alpha 2-macroglobulin and apolipoprotein E-enriched lipo
  
    59 ence-specific manner to the promoters of the alpha(2)-macroglobulin and Aalpha-fibrinogen genes and t
    60 istry revealed foci of albumin, transferrin, alpha(2)-macroglobulin and IgG transudation around blood
    61 rotein toxicity in the presence of activated alpha(2)-macroglobulin and its down-regulation via inhib
  
    63 nds receptor-associated protein or activated alpha(2)-macroglobulin and occurred primarily via a flui
    64  12 that contains the genes that encode both alpha(2)-macroglobulin and the low-density lipoprotein r
    65 ly that includes the pan-protease inhibitors alpha(2)-macroglobulins and vertebrate complement factor
    66 ivator (tPA), apolipoprotein E/lipoproteins, alpha(2)-macroglobulin, and the beta-amyloid precursor p
    67 revealed a receptor for the peptide PKRGFQD, alpha-2-macroglobulin, and for SNTRVAP, 78-kDa glucose-r
  
  
  
    71 roximately 7-fold) and the protein G-related alpha(2)-macroglobulin-binding protein (grab; approximat
  
  
    74 proteinase as shown by its ability to cleave alpha(2)-macroglobulin, but it does not cleave specific 
    75 acterized a novel member of the complement 3/alpha(2)-macroglobulin (C3/alpha(2)M) family named CPAMD
    76 angiotensin II-generating activity, and that alpha(2)-macroglobulin capture may be exploited in asses
  
    78 ntified mutations in CPAMD8 (C3 and PZP-like alpha-2-macroglobulin domain-containing protein 8) as th
    79 nterferon gene response (GAS) element in the alpha(2)-macroglobulin enhancer, Stat1 did not stimulate
    80  transient-transfection experiments with the alpha(2)-macroglobulin enhancer, Stat3 and c-Jun coopera
  
  
    83     The levels of five acute-phase proteins (alpha-2 macroglobulin, haptoglobin, serum amyloid P, pro
    84 g ectopic expression of modified versions of alpha(2)-macroglobulin in the treatment of fibrotic cond
    85  also demonstrated that genetically modified alpha(2)-macroglobulin, in which the native bait region 
    86  partially competitively inhibited by excess alpha(2)-macroglobulin, indicating that hspRs in additio
  
  
    89 These findings suggest that chymase bound to alpha(2)-macroglobulin is active, that the complex is an
  
  
    92 viously been reported that the serum protein alpha(2)-macroglobulin is unable to inhibit the astacin-
  
    94 nactivated alpha(1)-proteinase inhibitor and alpha(2)-macroglobulin lose the spreading activity, indi
    95 proteins, alpha 1-antichymotrypsin (ACT) and alpha 2-macroglobulin (MAC), and cognitive impairment in
    96 blood cells but precipitated only with human alpha(2)-macroglobulin, of many glycoproteins and polysa
    97 RP1 agonists (the receptor binding domain of alpha-2-macroglobulin or the hemopexin domain of matrix 
    98 he addition of excess CD91 ligand, activated alpha(2)-macroglobulin, or receptor-associated protein, 
    99 air synergy between STAT3-C and c-Jun at the alpha(2)-macroglobulin promoter in HepG2 cells, suggesti
   100 DNA elements contribute to activation of the alpha(2)-macroglobulin promoter in response to IL-6 fami
  
  
   103 hen scuPA bound to suPAR, a binding site for alpha 2-macroglobulin receptor/LDL receptor-related prot
   104 PE) binds and enters mammalian cells via the alpha 2-macroglobulin receptor/low density lipoprotein r
   105 scuPA to vitronectin, thombospondin, and the alpha 2-macroglobulin receptor/low-density lipoprotein-r
  
  
   108 rect association with the endocytic receptor alpha(2)-macroglobulin receptor/low density lipoprotein 
  
   110 ts were obtained for another ligand of LDLR, alpha-2-macroglobulin receptor-associated protein (RAP),
  
  
  
   114 A molecule related to the protease inhibitor alpha-2-macroglobulin responded strongly to malaria para
   115 d insulin-dependent regulation of macrophage alpha(2)-macroglobulin signaling receptors (alpha(2)MSR)
   116     Significant increases in serum levels of alpha-2-macroglobulin that correspond to changes in its 
  
   118 alpha and meprin beta, we herein demonstrate alpha(2)-macroglobulin to be a potent inhibitor of the s
   119 k(off)) for MMP-1 and MMP-3 determined using alpha(2)-macroglobulin to capture MMP dissociating from 
   120 ir ability to process peptides chaperoned by alpha(2) macroglobulin, undergo identical variations.   
   121 ession of transforming growth factor beta 1, alpha 2 macroglobulin, vascular endothelial growth facto
  
  
   124 ng antipeptidases, but is mostly captured by alpha(2)-macroglobulin, which sequesters peptidases in a
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。